Director James N. Wilson of Corcept Therapeutics Incorporated filed a Form 4 on November 17, 2026, disclosing the sale of 10,000 shares of common stock on November 13, 2026, executed under a Rule 10b5-1 plan.

Key Highlights

  • Reporting person: James N. Wilson, identified as a Director of Corcept Therapeutics Incorporated (NASDAQ:CORT).
  • Shares sold: A total of 10,000 shares of common stock were disposed of across four transactions on November 13, 2026.
  • Price range: Sales occurred at weighted average prices of $71.8011, $72.8666, $73.4192, and $74.28 per share, with individual sale prices ranging from $71.18 to $74.28 per share across all tranches.
  • 10b5-1 plan: All transactions were made pursuant to a Rule 10b5-1 plan adopted by Wilson on March 12, 2026.
  • Remaining indirect holdings: Following the transactions, Wilson holds 1,044,543 shares indirectly through the James N. Wilson and Pamela D. Wilson Trust, plus 200,000 shares in each of the James N. Wilson 2025 Grantor Retained Annuity Trust and the Pamela D. Wilson 2025 Grantor Retained Annuity Trust.
  • Voting disclaimer: According to the filing, Wilson "disclaims beneficial ownership of all of such shares, except to the extent of his pecuniary interest therein" for shares held in the James N. Wilson and Pamela D. Wilson Trust.

Wilson's Four-Tranche Sale of Corcept Common Stock on November 13, 2026

According to the Form 4 filing, Director James N. Wilson disposed of Corcept Therapeutics common stock in four separate tranches on November 13, 2026, all classified under transaction code "S" (sale). The first tranche covered 2,191 shares at a weighted average price of $71.8011, with actual prices ranging from $71.18 to $72.17 per share. The second tranche covered 7,221 shares at a weighted average of $72.8666, with actual prices from $72.18 to $73.155. The third tranche involved 563 shares at a weighted average of $73.4192, with actual prices from $73.22 to $73.88. The fourth tranche was 25 shares at $74.28 per share.

All four disposals were made indirectly through the James N. Wilson and Pamela D. Wilson Trust and were executed pursuant to a Rule 10b5-1 trading plan that Wilson adopted on March 12, 2026, as stated in the filing. The filing notes that exact per-share transaction details "can be obtained from the Issuer upon request."

After the reported transactions, the filing shows Wilson's indirect beneficial ownership through the James N. Wilson and Pamela D. Wilson Trust stood at 1,044,543 shares. The filing additionally discloses indirect holdings of 200,000 shares in the James N. Wilson 2025 Grantor Retained Annuity Trust and 200,000 shares in the Pamela D. Wilson 2025 Grantor Retained Annuity Trust. No direct share ownership is reported in this filing. The Form 4 was signed by Joseph Douglas Lyon as attorney-in-fact for James N. Wilson on November 17, 2026.

What Was Disclosed

This Form 4 discloses that Director James N. Wilson sold a total of 10,000 shares of Corcept Therapeutics common stock on November 13, 2026, through the James N. Wilson and Pamela D. Wilson Trust, under a pre-established Rule 10b5-1 plan adopted March 12, 2026.